All In Biotech

Drug Trial Radar · NCT02558829

Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency

Confirmatory Validation of Oral Macimorelin as a Growth Hormone (GH) Stimulation Test (ST) for the Diagnosis of Adult Growth Hormone Deficiency (AGHD) in Comparison With the Insulin Tolerance Test (ITT)

Last checked: Nov 20, 2026Latest source record: Apr 10, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 157 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

157

Actual

Start

Dec 3, 2015

Primary completion

Nov 29, 2016

Study completion Nov 29, 2016

Sponsor

Lead sponsor
AEterna ZentarisIndustry
Sponsor type
Industry
First posted
Sep 24, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The Macimorelin Growth Hormone Stimulation Test (GHST) will be compared with the Insulin Tolerance Test (ITT) in an open-label, randomized, 2-way crossover Trial. The trial will include subjects suspected to have adult growth hormone deficiency (AGHD) and a group of healthy control subjects.

Conditions

  • Growth Hormone Deficiency With Pituitary Anomalies

Interventions

  • MacimorelinDrug

    macimorelin acetate, 0.5 mg/kg body weight, drinking solution, single dose

  • InsulinDrug

    Insulin, 0.10 U/kg (0.15 U/kg if BMI \> 30 kg/m2), intravenous injection, single dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Co-primary Efficacy Variables: Percent Positive and Percent Negative Agreement of Macimorelin-GHST (MAC) With ITTTime frame: 90 minutes

Locations

27 sites in 9 countries. Site status is shown where the registry gives one.

  • Harbor UCLA Medical Center

    Torrance, California

  • Texas Diabetes and Endocrinology

    Austin, Texas

  • Baylor College of Medicine-Endocrinology

    Houston, Texas

  • VA Puget Sound Health Care System

    Seattle, Washington

  • Swedish Medical Center - Cherry Hill

    Seattle, Washington

  • Krankenanstalt Rudolfstiftung

    Vienna, Austria

  • Medical University & General Hospital of Vienna, AKH,

    Vienna, Austria

  • CHU de Lyon HCL-GH Est

    Bron, France

  • GHU Paris-Sud - Hôpital de Bicêtre

    Le Kremlin-Bicêtre, France

  • Hôpital Haut-Lévêque

    Pessac, France

  • Klinik für Endokrinologie, Diabetes und Ernährungsmedizin der Charité

    Berlin, Germany

  • Klinikum der LMU München

    Munich, Bavaria, Germany

  • Max Planck Institut

    Munich, Bavaria, Germany

  • University Hospital Marburg

    Marburg, Hesse, Germany

  • RWTH Aachen University Hospital

    Aachen, North Rhine-Westphalia, Germany

  • San Luca Hospital

    Milan, Italy

  • Centrum Kliniczno-Badawcze

    Elblag, Poland

  • Centrum Medyczne Angelius Provita

    Katowice, Poland

  • Phase I - MTZ Clinical Research Sp. z o.o.

    Warsaw, Poland

  • Wromedica

    Wroclaw, Poland

  • Clinical Centre of Serbia

    Belgrade, Serbia

  • Clinical Centre of Vojvodina

    Novi Sad, Serbia

  • Hospital de Sant Pau

    Barcelona, Spain

  • Hospital Universitari Vall d' Hebron

    Barcelona, Spain

  • Hospital de Conxo

    Santiago de Compostela, Spain

  • St Bartholomew's Hospital

    London, United Kingdom

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.